Aldeyra Therapeutics announced a significant change in its regulatory strategy for ADX-2191, its drug candidate for primary vitreoretinal lymphoma (PVRL). The company has requested that the U.S. FDA transfer the review of the drug's application to a different division and, in connection with this, has withdrawn its previously agreed-upon Special Protocol Assessment (SPA).
Key Details
- Regulatory Request: On November 9, 2026, Aldeyra asked the FDA's Division of Ophthalmology to transfer the review of the ADX-2191 application to the Division of Hematologic Malignancies 2, citing the latter's expertise in lymphomas.
- SPA Withdrawal: The company has formally withdrawn its Special Protocol Assessment (SPA), nullifying the prior agreement with the FDA on the clinical trial design and analysis plan for ADX-2191.
- Clinical Trial Delay: As a result of these actions, Aldeyra does not expect to initiate the planned clinical trial for PVRL while the transfer request is pending, creating significant uncertainty and potential delays for the program's regulatory path to approval.